Stay updated on Vertex Pharmaceuticals Press Releases

Sign up to get notified when there's something new on the Vertex Pharmaceuticals Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Vertex Pharmaceuticals Press Releases page

  1. Check
    13 days ago
    Change Detected
    Summary
    Vertex has announced its participation in upcoming November investor conferences and provided updates on its kidney programs at the ASN Annual Kidney Week, while recent deletions include a positive opinion for KAFTRIO and a Breakthrough Prize award.
    Difference
    7%
    Check dated 2024-11-01T11:40:41.000Z thumbnail image
  2. Check
    20 days ago
    Change Detected
    Summary
    Vertex has announced it will present Phase 3 data on Suzetrigine as a potential first-in-class pain signal inhibitor at the upcoming American Society of Anesthesiologists Annual Meeting on October 18, 2024, while a previous announcement regarding participation in the Morgan Stanley Healthcare Conference has been removed.
    Difference
    5%
    Check dated 2024-10-25T01:24:59.000Z thumbnail image
  3. Check
    28 days ago
    Change Detected
    Summary
    Vertex is set to announce its third quarter 2024 financial results on November 4th, while the recent appointment of E. Morrey Atkinson as EVP and Chief Technical Operations Officer has been removed from the updates.
    Difference
    4%
    Check dated 2024-10-17T20:11:45.000Z thumbnail image
  4. Check
    35 days ago
    No Change Detected
  5. Check
    42 days ago
    Change Detected
    Summary
    Vertex has added a significant update regarding the first oral presentation of Phase 3 clinical data for the Vanza Triple and new long-term impact data on TRIKAFTA® at the North American Cystic Fibrosis Conference, while a previous announcement about VX-548's Phase 2 results has been removed.
    Difference
    5%
    Check dated 2024-10-03T05:31:44.000Z thumbnail image
  6. Check
    78 days ago
    Change Detected
    Summary
    Vertex's stock price has decreased to $480.30, down 2.34 (-0.48%), with a new announcement regarding participation in upcoming September investor conferences.
    Difference
    3%
    Check dated 2024-08-28T03:41:04.000Z thumbnail image
  7. Check
    92 days ago
    Change Detected
    Summary
    The latest update includes a new reimbursement agreement for CASGEVY™ in England, while a previous approval for ORKAMBI® has been removed from the list.
    Difference
    4%
    Check dated 2024-08-14T01:16:22.000Z thumbnail image

Stay in the know with updates to Vertex Pharmaceuticals Press Releases

Enter your email address, and we'll notify you when there's something new on the Vertex Pharmaceuticals Press Releases page.